• Journal of Radiopharmaceuticals and Molecular Probes
• /
• v.9 no.1
• /
• pp.43-48
• /
• 2023

For over 50 years, boron neutron capture therapy (BNCT) has been steadily developed for treating various cancers. This is a non-invasive, selective, and targeted radiotherapy wherein boron-rich molecules accumulate at the tumor site. Liposomal vesicles have become a popular and effective drug delivery system for BNCT, with strategies including surface decoration, bilayer integration, and hydrophilic core encapsulation. This review highlights the state-of-the-art uses of liposomes in BNCT and elucidates a new perspective where BNCT can be used with radiotracer guidance in all-in-one delivery systems.

• Nuclear Engineering and Technology
• /
• v.49 no.1
• /
• pp.189-195
• /
• 2017

Gel dosimeters have unique advantages in comparison with other dosimeters. Until now, these gels have been used in different radiotherapy techniques as a reliable dosimetric tool. Because dose distribution measurement is an important factor for appropriate treatment planning in different radiotherapy techniques, in this study, we evaluated the ability of the N-isopropylacrylamide (NIPAM) polymer gel to record the dose distribution resulting from the mixed neutron-gamma field of boron neutron capture therapy (BNCT). In this regard, a head phantom containing NIPAM gel was irradiated using the Tehran Research Reactor BNCT beam line, and then by a magnetic resonance scanner. Eventually, the $R_2$ maps were obtained in different slices of the phantom by analyzing T2-weighted images. The results show that NIPAM gel has a suitable potential for recording three-dimensional dose distribution in mixed neutron-gamma field dosimetry.

• Nuclear Engineering and Technology
• /
• v.56 no.5
• /
• pp.1813-1821
• /
• 2024

Beam shaping assembly (BSA) is a vital component in Boron Neutron Capture Therapy (BNCT) for obtaining epithermal neutron beams. Several feasible designs of BSA for accelerator-based BNCT (AB-BNCT) neutron source are carried out based on neutrons by bombarding a natural lithium target with 10 mA, 2.8 MeV proton beams. The calculation results demonstrate that a thickness of 45 cm is appropriate for general moderators referring to the therapeutic parameter of Advanced Depth (AD). A series of optimizations are performed and two results are confirmed: One is that employing the configuration of MgF₂ and FLUENTAL combined by 1:1 could improve the therapeutic rate (TR) of tumors at a depth of middle region, and the other one is that the TR of superficial tumors can be increased by adding a 5 cm thick boron-11 secondary moderator at the end of general moderators. As a result, an innovative conception of an adjustable moderator is recommended to BNCT. Compared to the MgF₂ moderator with a fixed thickness of 45 cm, the TR value can be improved by a maximum of 47.7 % by using the adjustable moderator. Furthermore, the configuration of adjustable moderator has been designed with regulation method for treating tumors of different depths.

• Nuclear Engineering and Technology
• /
• v.53 no.2
• /
• pp.626-636
• /
• 2021

Boron-neutron capture therapy (BNCT) is a cancer treatment method that exploits the high neutron reactivity of boron. Monitoring the prompt gamma rays (PGs) produced during neutron irradiation is essential for ensuring the accuracy and safety of BNCT. We investigate the imaging of PGs produced by the boron-neutron capture reaction through Monte Carlo simulations of a gamma camera with a SrI₂ scintillator and parallel-hole collimator. GAGG scintillator is also used for a comparison. The simulations allow the shapes of the energy spectra, which exhibit a peak at 478 keV, to be determined along with the PG images from a boron-water phantom. It is found that increasing the size of the water phantom results in a greater number of image counts and lower contrast. Additionally, a higher septal penetration ratio results in poorer image quality, and a SrI₂ scintillator results in higher image contrast. Thus, we can simulate the BNCT process and obtain an energy spectrum with a reasonable shape, as well as suitable PG images. Both GAGG and SrI₂ crystals are suitable for PG imaging during BNCT. However, for higher imaging quality, SrI₂ and a collimator with a lower septal penetration ratio should be utilized.

• Proceedings of the KIPE Conference
• /
• 2018.07a
• /
• pp.638-641
• /
• 2018

현재 선진국에서는 고출력 양성자 선형 가속기를 기반으로 한 의료용 암치료기인 BNCT(Boron Neutron Capture Therapy)에 대해 활발히 연구 중이며 다원시스도 2016년부터 A-BNCT 사업을 진행 중이다. A-BNCT에 적용된 양성자 선형 가속기의 RF(Radio Frequency)전원을 공급하기 위해 352 MHz, 1.5 MW의 고출력을 가지는 클라이스트론을 사용하였다. 클라이스트론의 출력인 RF의 크기와 위상을 안정적으로 제어하기 위해 90 kV, 30 A, 120 Hz, 1.7 ms의 구형파 출력을 가지는 고전압 전원장치를 적용하였다. 또한 고전압 전원장치의 출력전압 변동률을 0.5% 이내로 유지시키기 위해 전압보상회로를 적용하여 회로 시뮬레이션과 실부하 실험을 통해 펄스전원장치의 성능을 검증하였다.

• Nuclear Engineering and Technology
• /
• v.52 no.9
• /
• pp.2072-2077
• /
• 2020

The purpose of this study was to demonstrate the feasibility of sensing changes in a tumor during boron neutron capture therapy (BNCT) using a Monte Carlo simulation tool. In the simulation, an epi-thermal neutron source and a water phantom including boron uptake regions (BURs) were simulated. Moreover, this simulation also included a detector for positron emission tomography (PET) scanning and an adaptively-designed collimator (ADC) for PET. After the PET scanning of the water phantom, including the 511 keV source in the BUR, the ADC was positioned in the PET's gantry. Single prompt gamma rays were collected through the ADC during neutron irradiation. Then, single prompt gamma ray-based tomography images of different sized tumors were acquired by a four-step process. Both the signal-to-noise ratio (SNR) and tumor size were analyzed from each step image. From this analysis, we identified a decreasing trend of both the SNR and signal intensity as the tumor size decreased, which was confirmed in all images. In conclusion, we confirmed the feasibility of sensing changes in a tumor during BNCT using PET and an ADC through Monte Carlo simulation.

• Proceedings of the Korean Nuclear Society Conference
• /
• 1997.05b
• /
• pp.427-432
• /
• 1997

Boron neutron capture therapy(BNCT) is a binary treatment modality that can selectively irradiate tumor tissue. More is known now about the radiation biology of BNCT, which has reemerged as a potentially useful method for preferential irradiation of tumors. We design a square reactor (that can easily be reconfigured into polygonal reactors as the need arises) with four slab type assemblies to produce high quality epithermal neutron beans and thermal neutron beams jot use in neutron capture therapy. With a low operating power of 300kW, the heat generated in the core can be removed by natural convection through a pool of tight water. The proposed design in this study could be constructed for a dedicated clinical BNCT facility that would operate very safely.

• Journal of Radiopharmaceuticals and Molecular Probes
• /
• v.8 no.1
• /
• pp.17-23
• /
• 2022

Boron neutron capture therapy is a precision treatment technology that selectively destroys only tumor cells by irradiating thermal neutrons after accumulating boron drugs in tumor cells. Brain tumor is difficult to diagnose and treat due to the low permeability and targeting of drugs caused by the blood-brain-barrier. Crossing the BBB is essential for drug delivery to the brain. In this study, we designed and synthesized a novel compound incorporating benzothiazole to develop a boron drug with high BBB permeability and selectivity for brain tumor cells. In addition, their potential as a BNCT drugs was evaluated.

• Nuclear Engineering and Technology
• /
• v.55 no.7
• /
• pp.2419-2431
• /
• 2023

Experiments related to Boron Neutron Capture Therapy (BNCT) accomplished at the Institute of Nuclear Techniques (INT), Budapest University of Technology and Economics (TUB) are presented. Relevant investigations are required before designing BNCT for vivo applications. Samples of relevant boron compounds (H₃BO₃, BDTPA) usually employed in BNCT were investigated with neutron beam. Channel #5 in the research reactor (100 kW) of INT-TUB provides the neutron beam. Boron samples are mounted on a carrier for neutron irradiation. The particle attenuation of several carrier materials was investigated, and the one with the lowest attenuation was selected. The effects of boron compound type, mass, and compound phase state were also investigated. To detect the emitted charged particles, a traditional ZnS(Ag) detector was employed. The neutron beam's interaction with the detector-detecting layer is investigated. Graphite (as a moderator) was employed to change the neutron beam's characteristics. The fast neutron beam was also thermalized by placing a portable fast neutron source in a paraffin container and irradiating the H₃BO₃. The obtained results suggest that the direct measurement approach appears to be insufficiently sensitive for determining the radiation dose committed by the Alpha particles from the ¹⁰B (n,α) reaction. As a result, a new approach must be used.

• Journal of Radiopharmaceuticals and Molecular Probes
• /
• v.6 no.1
• /
• pp.10-19
• /
• 2020

Boron Neutron Capture Therapy (BNCT) has the advantage of selectively removing cancer cells ingesting boron compounds. In this study, the benefits for treatment time and boron compound injection dose were compared between current neutron sources and a high current neutron sources to be developed in near future. The time-activity curve (TAC) of GBM (Glioblastoma) for one bolus injection was obtained by applying modified 3 compartment model. The treatment time was determined for an accelerator-based neutron sources at the present time and a high current accelerator based neutron source to be developed in the near future. In the case of the double amount of IAEA-recommended neutron flux, the treatment time was shortened to 15 minutes. In the case of high current accelerators, which are five times the amount of IAEA-recommended neutron flux, the irradiation time is within 5 minutes. The use of a high current accelerator based neutron source in BNCT is advantageous in terms of treatment time. In addition, it can increase the efficiency of use of neutrons and reduce the boron compound injection dose to patients, thus reducing pharmacological toxicity.